Drug Profile
Ibandronic acid - Lanco Biosciences
Alternative Names: Ibadronate - Lanco Biosciences; LBS-101Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Lanco Biosciences
- Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
- Mechanism of Action Bone resorption factor inhibitors; Dimethylallyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Osteoporosis
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Osteoporosis in USA (Transdermal)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Osteoporosis in USA (Transdermal, Needle-free injection)
- 26 Aug 2016 Chemical structure information added